Prevalence and Risk Factors of Sexually Transmitted Infections and Cervical Neoplasia in Women from a Rural Area of Southern Mozambique
Table 4
Prevalence and risk of STIs and cervical neoplasia by HIV status.
STD by HIV
HIV (−)
HIV (+)
Adjusted* OR
95% Cl
%
%
Gonococcal infection
27
12
6
20
1.9
(0.7; 5.5)
.219
Syphilis (RPR & IgG)
26
12
5
17
1.6
(0.5; 4.5)
.408
HPV DNA
83
37
14
47
1.6
(0.7; 3.5)
.262
HSV-2 antibodies
185
82
27
90
2.1
(0.6; 7.6)
.259
Chlamydia trachomatis DNA
14
6
5
17
3.1
(1.0; 9.6)
.051
Trichomona vaginalis
67
30
9
30
1.0
(0.4; 2.4)
.966
HBsAg anribodies
19
8
1
3
0.4
(0.1; 3.0)
.359
Anti-HBc antibodies
137
61
22
73
1.8
(0.8; 4.3)
.172
Any treatable STI**
107
47
18
60
1.7
(0.8; 3.8)
.190
Cervical neoplasia
23
10
6
20
2.5
(0.9; 7.0)
.088
*Adjusted by age and ethnic group.
**Any treatable STI: syphilis (RPR confirmed by IgG), gonococcal infection, trichomona vaginalis or chlamydia trachomatis.
